{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:34:38Z","timestamp":1778945678674,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40265-020-01265-4","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T14:02:34Z","timestamp":1580824954000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Rise and Fall \u201cing\u201d of the HDL Hypothesis"],"prefix":"10.1007","volume":"80","author":[{"given":"Julien J.","family":"Feghaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8177-7668","authenticated-orcid":false,"given":"Arshag D.","family":"Mooradian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","volume":"282","author":"JC LaRosa","year":"1999","unstructured":"LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340\u20136.","journal-title":"JAMA"},{"key":"1265_CR2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","volume":"125","author":"RS Rosenson","year":"2012","unstructured":"Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905\u201319.","journal-title":"Circulation"},{"key":"1265_CR3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/bi011716p","volume":"41","author":"JK Bielicki","year":"2002","unstructured":"Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41:2089\u201396.","journal-title":"Biochemistry"},{"issue":"12","key":"1265_CR4","doi-asserted-by":"crossref","first-page":"e0144372","DOI":"10.1371\/journal.pone.0144372","volume":"10","author":"SJ Cameron","year":"2015","unstructured":"Cameron SJ, Morrell CN, Bao C, Swaim AF, Rodriguez A, Lowenstein CJ. A novel anti-inflammatory effect for high density lipoprotein. PLoS One. 2015;10(12):e0144372.","journal-title":"PLoS One"},{"key":"1265_CR5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.ATV.18.9.1450","volume":"18","author":"DT Ashby","year":"1998","unstructured":"Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1450\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1265_CR6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1172\/JCI113682","volume":"82","author":"Y Yui","year":"1988","unstructured":"Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Investig. 1988;82:803\u20137.","journal-title":"J Clin Investig"},{"issue":"3","key":"1265_CR7","doi-asserted-by":"crossref","first-page":"e0192616","DOI":"10.1371\/journal.pone.0192616","volume":"13","author":"T Vaisar","year":"2018","unstructured":"Vaisar T, Couzens E, Hwang A, Russell M, Barlow CE, DeFina LF, Hoofnagle AN, Kim F. Type 2 diabetes is associated with loss of HDL endothelium protective functions. PLoS One. 2018;13(3):e0192616.","journal-title":"PLoS One"},{"key":"1265_CR8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood-2014-09-599530","volume":"127","author":"DW Chung","year":"2016","unstructured":"Chung DW, Chen J, Ling M, Fu X, Blevins T, Parsons S, Le J, Harris J, Martin TR, Konkle BA, Zheng Y, L\u00f3pez JA. High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood. 2016;127:637\u201345.","journal-title":"Blood"},{"key":"1265_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707\u201314.","journal-title":"Am J Med"},{"key":"1265_CR10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292\u2013333.","journal-title":"Circulation"},{"key":"1265_CR11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","volume":"128","author":"SM Boekholdt","year":"2013","unstructured":"Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128:1504\u201312.","journal-title":"Circulation"},{"key":"1265_CR12","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1210\/jc.2014-2365","volume":"99","author":"B Verg\u00e8s","year":"2014","unstructured":"Verg\u00e8s B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, et al. Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. J Clin Endocrinol Metab. 2014;99:4281\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"1265_CR13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/oby.2011.323","volume":"20","author":"MJ Haas","year":"2012","unstructured":"Haas MJ, Mazza AD, Wong NC, Mooradian AD. Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. Obesity (Silver Spring). 2012;20:721\u20139.","journal-title":"Obesity (Silver Spring)"},{"key":"1265_CR14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/oby.2008.202","volume":"16","author":"AD Mooradian","year":"2008","unstructured":"Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring). 2008;16:1152\u201360.","journal-title":"Obesity (Silver Spring)"},{"key":"1265_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(99)00473-6","volume":"152","author":"L Duvillard","year":"2000","unstructured":"Duvillard L, Pont F, Florentin E, Gambert P, Verg\u00e8s B. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis. 2000;152:229\u201337.","journal-title":"Atherosclerosis"},{"key":"1265_CR16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2337\/diabetes.53.3.513","volume":"53","author":"AD Mooradian","year":"2004","unstructured":"Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 2004;53:513\u201320.","journal-title":"Diabetes"},{"key":"1265_CR17","doi-asserted-by":"crossref","first-page":"18959","DOI":"10.1074\/jbc.273.30.18959","volume":"273","author":"K Murao","year":"1998","unstructured":"Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NC. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem. 1998;273:18959\u201365.","journal-title":"J Biol Chem"},{"key":"1265_CR18","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1021\/bi026984h","volume":"42","author":"JK Lam","year":"2003","unstructured":"Lam JK, Matsubara S, Mihara K, Zheng XL, Mooradian AD, Wong NC. Insulin induction of apolipoprotein AI, role of Sp1. Biochemistry. 2003;42:2680\u201390.","journal-title":"Biochemistry"},{"key":"1265_CR19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1463-1326.2006.00636.x","volume":"9","author":"AD Mooradian","year":"2007","unstructured":"Mooradian AD, Albert SG, Haas MJ. Low serum high-density lipoprotein cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes Metab. 2007;9:441\u20133.","journal-title":"Diabetes Obes Metab"},{"key":"1265_CR20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QCO.0b013e328344b724","volume":"24","author":"MJ Haas","year":"2011","unstructured":"Haas MJ, Mooradian AD. Inflammation, high-density lipoprotein and cardiovascular dysfunction. Curr Opin Infect Dis. 2011;24:265\u201372.","journal-title":"Curr Opin Infect Dis"},{"key":"1265_CR21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/dmrr.1057","volume":"26","author":"MJ Haas","year":"2010","unstructured":"Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab Res Rev. 2010;26:90\u20139.","journal-title":"Diabetes Metab Res Rev"},{"key":"1265_CR22","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1021\/bi0518040","volume":"45","author":"A Beers","year":"2006","unstructured":"Beers A, Haas MJ, Wong NC, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK\/ERK and JNK signaling. Biochemistry. 2006;45:2408\u201313.","journal-title":"Biochemistry"},{"key":"1265_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jcb.24656","volume":"115","author":"S Parseghian","year":"2014","unstructured":"Parseghian S, Onstead-Haas LM, Wong NC, Mooradian AD, Haas MJ. Inhibition of apolipoprotein A-I expression by TNF-alpha in HepG2 cells: requirement for c-jun. J Cell Biochem. 2014;115:253\u201360.","journal-title":"J Cell Biochem"},{"issue":"2\u20133","key":"1265_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbagen.2003.08.004","volume":"1623","author":"MJ Haas","year":"2003","unstructured":"Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NC, Mooradian AD. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochim Biophys Acta. 2003;1623(2\u20133):120\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"1265_CR25","first-page":"150","volume":"41","author":"C Palacio","year":"2011","unstructured":"Palacio C, Alexandraki I, Bertholf RL, Mooradian AD. Transient dyslipidemia mimicking the plasma lipid profile of Tangier disease in a diabetic patient with gram negative sepsis. Ann Clin Lab Sci. 2011;41:150\u20133.","journal-title":"Ann Clin Lab Sci"},{"key":"1265_CR26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lfs.2012.06.002","volume":"91","author":"E Naem","year":"2012","unstructured":"Naem E, Alcalde R, Gladysz M, Mesliniene S, Jaimungal S, Sheikh-Ali M, Haas MJ, Wong NC, Mooradian AD. Inhibition of apolipoprotein A-I gene by the aryl hydrocarbon receptor: a potential mechanism for smoking-associated hypoalphalipoproteinemia. Life Sci. 2012;91:64\u20139.","journal-title":"Life Sci"},{"key":"1265_CR27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MJT.0b013e3182838e47","volume":"21","author":"AD Mooradian","year":"2014","unstructured":"Mooradian AD. Is high-density lipoprotein cardioprotective or simply a marker of cardiovascular disease? Am J Ther. 2014;21:438\u20139.","journal-title":"Am J Ther"},{"key":"1265_CR28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.18632\/aging.100242","volume":"3","author":"AB Newman","year":"2011","unstructured":"Newman AB, Glynn NW, Taylor CA, et al. Health and function of participants in the Long Life Family Study: a comparison with other cohorts. Aging (Albany, NY). 2011;3:63\u201376.","journal-title":"Aging (Albany, NY)"},{"key":"1265_CR29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.amjcard.2010.12.015","volume":"107","author":"CR Rahilly-Tierney","year":"2011","unstructured":"Rahilly-Tierney CR, Spiro A, Vokonas P, Gaziano JM. Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA Normative Aging Study). Am J Cardiol. 2011;107:1173\u20137.","journal-title":"Am J Cardiol"},{"key":"1265_CR30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.atherosclerosis.2014.09.012","volume":"237","author":"MC Odden","year":"2014","unstructured":"Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. 2014;237:336\u201342.","journal-title":"Atherosclerosis"},{"key":"1265_CR31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199108083250601","volume":"325","author":"MJ Stampfer","year":"1991","unstructured":"Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373\u201381.","journal-title":"N Engl J Med"},{"key":"1265_CR32","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1172\/JCI117603","volume":"94","author":"JC Cohen","year":"1994","unstructured":"Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI\/CIII\/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Investig. 1994;94:2377\u201384.","journal-title":"J Clin Investig"},{"key":"1265_CR33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000006849","volume":"90","author":"JR Reguero","year":"1998","unstructured":"Reguero JR, Cubero GI, Batalla A, et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary disease. Cardiology. 1998;90:231\u20135.","journal-title":"Cardiology"},{"issue":"9841","key":"1265_CR34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572\u201380.","journal-title":"Lancet"},{"key":"1265_CR35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40265-015-0390-1","volume":"75","author":"AD Mooradian","year":"2015","unstructured":"Mooradian AD, Haas MJ. Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance. Drugs. 2015;75:713\u201322.","journal-title":"Drugs"},{"key":"1265_CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.gene.2003.11.024","volume":"327","author":"L Pastore","year":"2004","unstructured":"Pastore L, Belalcazar LM, Oka K, et al. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene. 2004;327:153\u201360.","journal-title":"Gene"},{"key":"1265_CR37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.atherosclerosis.2010.05.035","volume":"212","author":"S Patel","year":"2010","unstructured":"Patel S, Di Bartolo BA, Nakhla S, et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis. 2010;212:392\u20137.","journal-title":"Atherosclerosis"},{"key":"1265_CR38","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292.","journal-title":"JAMA"},{"key":"1265_CR39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071\u201380.","journal-title":"JAMA"},{"key":"1265_CR40","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016;351:1166\u201371.","journal-title":"Science"},{"key":"1265_CR41","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1194\/jlr.M300511-JLR200","volume":"45","author":"CC Schwartz","year":"2004","unstructured":"Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45:1594\u2013607.","journal-title":"J Lipid Res"},{"key":"1265_CR42","unstructured":"Allard-Ratick M. Association between very high levels of HDL-c and increased risk of CV events. In: Atlanta: ESC; 2018. https:\/\/ipccs.org\/2018\/09\/04\/association-between-very-high-levels-of-hdl-c-and-increased-risk-of-cv-events\/. Accessed Aug 6, 2019."},{"key":"1265_CR43","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1210\/jc.2011-1846","volume":"97","author":"CL Haase","year":"2012","unstructured":"Haase CL, Tybj\u00e6rg-Hansen A, Ali Qayyum A, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"1265_CR44","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.2337\/db15-1668","volume":"65","author":"JTM Tan","year":"2016","unstructured":"Tan JTM, Prosser HCG, Dunn LL, et al. High-density lipoproteins rescue diabetes-impaired angiogenesis via scavenger receptor class B type I. Diabetes. 2016;65:3091\u2013103.","journal-title":"Diabetes"},{"key":"1265_CR45","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.114.303720","volume":"34","author":"A Gille","year":"2014","unstructured":"Gille A, Easton R, D\u2019Andrea D, Wright SD, Shear CL. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol. 2014;34:2106\u201314.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1265_CR46","doi-asserted-by":"crossref","first-page":"e002171","DOI":"10.1161\/JAHA.115.002171","volume":"4","author":"P Tricoci","year":"2015","unstructured":"Tricoci P, D\u2019Andrea DM, Gurbel PA, et al. Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial. J Am Heart Assoc. 2015;4(8):e002171.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"1265_CR47","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"J-C Tardif","year":"2007","unstructured":"Tardif J-C, Gr\u00e9goire J, L\u2019Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675\u201382.","journal-title":"JAMA"},{"key":"1265_CR48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1194\/jlr.M055665","volume":"56","author":"RS Kootte","year":"2015","unstructured":"Kootte RS, Smits LP, van der Valk FM, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015;56:703\u201312.","journal-title":"J Lipid Res"},{"key":"1265_CR49","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ahj.2015.01.008","volume":"169","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Smits LP, Stefanutti C, et al. The effect of an apolipoprotein A-I\u2013containing high-density lipoprotein\u2013mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. Am Heart J. 2015;169:736\u201342.","journal-title":"Am Heart J"},{"key":"1265_CR50","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"J-C Tardif","year":"2014","unstructured":"Tardif J-C, Ballantyne CM, Barter P, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35:3277\u201386.","journal-title":"Eur Heart J"},{"key":"1265_CR51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jamacardio.2018.2112","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT Trial: a randomized clinical trial. JAMA Cardiol. 2018;3:806\u201314.","journal-title":"JAMA Cardiol"},{"key":"1265_CR52","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Andrews J, Kastelein JJP, et al. Effect of serial infusions of CER-001, a pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: a randomized clinical trial. JAMA Cardiol. 2018;3:815\u201322.","journal-title":"JAMA Cardiol"},{"key":"1265_CR53","unstructured":"Duffy D. Study to investigate CSL112 in subjects with acute coronary syndrome (AEGIS-II)\u2014NCT03473223. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03473223. Accessed Aug 8, 2019."},{"key":"1265_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40265-013-0023-5","volume":"73","author":"JM Chehade","year":"2013","unstructured":"Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology and management. Drugs. 2013;73:327\u201339.","journal-title":"Drugs"},{"key":"1265_CR55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/978-3-030-11815-0_38","volume-title":"The diabetes textbook. Clinical principles, patient management and public health issues","author":"AD Mooradian","year":"2019","unstructured":"Mooradian AD. Diabetes and atherogenic dyslipidemia. In: Rodriguez-Saldana SJ, editor. The diabetes textbook. Clinical principles, patient management and public health issues. Basel: Springer Nature; 2019. p. 587\u201396."},{"key":"1265_CR56","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410\u20138.","journal-title":"N Engl J Med"},{"key":"1265_CR57","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-Prevention Trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237\u201345.","journal-title":"N Engl J Med"},{"key":"1265_CR58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","author":"The BIP Study Group","year":"2000","unstructured":"The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102:21\u20137.","journal-title":"Circulation"},{"key":"1265_CR59","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"FIELD Study Investigators","year":"2005","unstructured":"FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"1265_CR60","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"The ACCORD Study Group","year":"2010","unstructured":"The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"1265_CR61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","volume":"2","author":"MB Elam","year":"2017","unstructured":"Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370\u201380.","journal-title":"JAMA Cardiol"},{"key":"1265_CR62","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","unstructured":"The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"1265_CR63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"1265_CR64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/er.2005-0013","volume":"27","author":"AD Mooradian","year":"2006","unstructured":"Mooradian AD, Haas MJ, Wong NCW. The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev. 2006;27:2\u201316.","journal-title":"Endocr Rev"},{"key":"1265_CR65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/9783527625178.ch16","volume-title":"High density lipoproteins. From basic biology to clinical aspects","author":"AD Mooradian","year":"2007","unstructured":"Mooradian AD. The effect of nutrients on apolipoprotein AI gene expression. In: Fielding CJ, editor. High density lipoproteins. From basic biology to clinical aspects. Weinheim: Wiley-VCH; 2007. p. 399\u2013423."},{"key":"1265_CR66","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.metabol.2004.05.011","volume":"53","author":"MJ Haas","year":"2004","unstructured":"Haas MJ, Horani MH, Wong NCW, Mooradian AD. Induction of apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. Metabolism. 2004;53:1342\u20138.","journal-title":"Metabolism"},{"key":"1265_CR67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40256-019-00336-6","volume":"19","author":"AD Mooradian","year":"2019","unstructured":"Mooradian AD. Evidence based cardiovascular risk management in diabetes. Am J Cardiovasc Drugs. 2019;19:439\u201348.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1265_CR68","first-page":"150","volume":"5","author":"AD Mooradian","year":"2009","unstructured":"Mooradian AD. Dyslipidemia of type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150\u20139.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1265_CR69","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1185\/03007991003645318","volume":"26","author":"HE Bays","year":"2010","unstructured":"Bays HE, Maki KC, McKenney J, et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hyper-triglyceridemic patients. Curr Med Res Opin. 2010;26:907\u201315.","journal-title":"Curr Med Res Opin"},{"key":"1265_CR70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"D Bhatt","year":"2019","unstructured":"Bhatt D, Steg PG, Michael Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322.","journal-title":"N Engl J Med"},{"key":"1265_CR71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309\u201318.","journal-title":"N Engl J Med"},{"key":"1265_CR72","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540\u201350.","journal-title":"N Engl J Med"},{"key":"1265_CR73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23\u201332.","journal-title":"N Engl J Med"},{"key":"1265_CR74","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","volume":"41","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281\u20138.","journal-title":"Clin Cardiol"},{"key":"1265_CR75","unstructured":"Anon. Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia (AstraZeneca press release dated January 13, 2020). https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html. Accessed 22 Jan 2020."},{"key":"1265_CR76","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med"},{"key":"1265_CR77","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u201399.","journal-title":"N Engl J Med"},{"key":"1265_CR78","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933\u201342.","journal-title":"N Engl J Med"},{"key":"1265_CR79","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"The HPS3\/TIMI55\u2013REVEAL Collaborative Group","year":"2017","unstructured":"The HPS3\/TIMI55\u2013REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217\u201327.","journal-title":"N Engl J Med"},{"key":"1265_CR80","unstructured":"A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent acute coronary syndrome (ACS): the Dal-GenE Trial. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02525939. Accessed Jan, 2020."},{"key":"1265_CR81","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11535410-000000000-00000","volume":"70","author":"MJ Haas","year":"2010","unstructured":"Haas MJ, Mooradian AD. Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. Drugs. 2010;70:805\u201321.","journal-title":"Drugs"},{"key":"1265_CR82","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1089\/adt.2017.782","volume":"15","author":"MJ Haas","year":"2017","unstructured":"Haas MJ, Onstead-Haas L, Kurban W, et al. High-throughput analysis identifying drugs that regulate apolipoprotein A-I synthesis. Assay Drug Dev Technol. 2017;15:362\u201371.","journal-title":"Assay Drug Dev Technol"},{"key":"1265_CR83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2018.01.035","volume":"823","author":"MJ Haas","year":"2018","unstructured":"Haas MJ, Plazarte M, Chamseddin A, et al. Inhibition of hepatic apolipoprotein A-I gene expression by histamine. Eur J Pharmacol. 2018;823:49\u201357.","journal-title":"Eur J Pharmacol"},{"key":"1265_CR84","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lfs.2018.07.022","volume":"208","author":"MJ Haas","year":"2018","unstructured":"Haas MJ, Jurado-Flores M, Hammoud R, et al. Regulation of apolipoprotein A-I gene expression by the histamine H1 receptor: Requirement for NF-\u03baB. Life Sci. 2018;208:102\u201310.","journal-title":"Life Sci"},{"key":"1265_CR85","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","volume":"55","author":"D Bailey","year":"2010","unstructured":"Bailey D, Jahagirdar R, Gordon A, et al. RVX-208. J Am Coll Cardiol. 2010;55:2580\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1265_CR86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10557-012-6373-5","volume":"26","author":"SJ Nicholls","year":"2012","unstructured":"Nicholls SJ, Gordon A, Johannson J, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012;26:181\u20137.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1265_CR87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","volume":"16","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE Trial. Am J Cardiovasc Drugs. 2016;16:55\u201365.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"1265_CR88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40256-018-0298-8","volume":"19","author":"D Shishikura","year":"2019","unstructured":"Shishikura D, Kataoka Y, Honda S, et al. The effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque: Insights from the ASSURE Trial. Am J Cardiovasc Drugs. 2019;19(1):49\u201357. https:\/\/doi.org\/10.1007\/s40256-018-0298-8.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"1265_CR89","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","volume":"18","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Ray KK, Johansson JO, et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs. 2018;18(2):109\u201315. https:\/\/doi.org\/10.1007\/s40256-017-0250-3.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1265_CR90","unstructured":"Effect of BET protein inhibition with apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes\u2014BETonMACE. https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2019\/11\/15\/17\/25\/betonmace. Accessed Jan 2020."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01265-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01265-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01265-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:40:35Z","timestamp":1612312835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01265-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01265-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"4 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julien J. Feghaly and Arshag D. Mooradian declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}